Suppr超能文献

新辅助放化疗时代超低位前切除术的围手术期结局

Perioperative outcomes after ultra low anterior resection in the era of neoadjuvant chemoradiotherapy.

作者信息

Shrikhande Shailesh V, Bodhankar Yashodhan D, Suradkar Kunal, Goel Mahesh, Shukla Parul J

机构信息

Department of Gastrointestinal and Hepato-Pancreato-Biliary Surgical Oncology, Tata Memorial Centre, Dr. Ernest Borges Marg, Parel, Mumbai 400 012, India.

出版信息

Indian J Gastroenterol. 2013 Mar;32(2):90-7. doi: 10.1007/s12664-012-0193-1. Epub 2012 Aug 14.

Abstract

PURPOSE

Data on perioperative outcomes of sphincter preserving ultra low anterior resections (ULAR) following neoadjuvant chemoradiotherapy (NA-CTRT) is sparsely reported in literature.

METHODS

Prospective data of 68 patients was reviewed retrospectively. Patients who received preoperative chemoradiotherapy (CTRT, Group A, n = 45) were compared with those who were operated upfront (Group B, n = 23).

RESULTS

Overall, mean distance of the tumor from anal verge was 5.1 cm (range 3-8). In Groups A and B, it was 5.2 and 5.1 cm, respectively. In Group A, 3 patients had complete response, 40 had partial response and 2 had progressive disease. Overall, the mean distance of the anastomosis performed from the anal verge was 2.8 cm (range 1-4). In Groups A and B, it was 2.7 and 2.9 cm, respectively (NS). Mean blood loss in Groups A and B was 510.5 (range 200-2,200) and 345 mL (range 50-800), respectively (p = 0.037). Two patients in Group A required blood transfusion (range 1-2) compared to none in Group B. The overall complication rate was 26.5 % (18/68); in Groups A and B, it was 22.2 % and 34.8 %, respectively. There was no postoperative mortality. Postoperative stay for Groups A and B was 8 and 9.5 days (p = 0.009), respectively. In Group A, 23/45 patients, earlier planned for abdominoperineal resection, ultimately received sphincter-preserving ULAR.

CONCLUSION

ULAR can be performed safely without added morbidity or mortality after neoadjuvant chemoradiation. In some cases, earlier deemed to be suitable for APR, the neoadjuvant approach improved chances of sphincter conservation.

摘要

目的

关于新辅助放化疗(NA-CTRT)后保留括约肌的超低位前切除术(ULAR)围手术期结果的数据在文献中报道较少。

方法

回顾性分析68例患者的前瞻性数据。将接受术前放化疗的患者(CTRT组,A组,n = 45)与直接接受手术的患者(B组,n = 23)进行比较。

结果

总体而言,肿瘤距肛缘的平均距离为5.1 cm(范围3 - 8 cm)。A组和B组分别为5.2 cm和5.1 cm。A组中,3例患者完全缓解,40例部分缓解,2例疾病进展。总体而言,吻合口距肛缘的平均距离为2.8 cm(范围1 - 4 cm)。A组和B组分别为2.7 cm和2.9 cm(无统计学差异)。A组和B组的平均失血量分别为510.5 mL(范围200 - 2200 mL)和345 mL(范围50 - 800 mL)(p = 0.037)。A组有2例患者需要输血(范围1 - 2次),而B组无输血患者。总体并发症发生率为26.5%(18/68);A组和B组分别为22.2%和34.8%。无术后死亡病例。A组和B组的术后住院时间分别为8天和9.5天(p = 0.009)。在A组中,最初计划行腹会阴联合切除术的45例患者中有23例最终接受了保留括约肌的ULAR手术。

结论

新辅助放化疗后,ULAR手术可安全进行,且不会增加发病率或死亡率。在某些情况下,对于早期被认为适合行腹会阴联合切除术的患者,新辅助治疗方法提高了保留括约肌的几率。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验